Document Detail

Febuxostat for treatment of chronic gout.
MedLine Citation:
PMID:  21330679     Owner:  NLM     Status:  Publisher    
Purpose The pharmacology, pharmacokinetics, clinical efficacy, and safety of febuxostat are reviewed. Summary Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid production through selective inhibition of enzyme xanthine oxidase has been established in short-term Phase II and III clinical trials and long-term open-label studies. Clinical studies have revealed that febuxostat lowers serum uric acid levels more potently than allopurinol while having minimal effects on other enzymes associated with purine and pyrimide metabolism. The most frequent adverse events reported in clinical trials with febuxostat were liver function abnormalities, nausea, arthralgias, and rash. More cardiovascular thromboembolic events occurred in randomized trials in patients treated with febuxostat. Although a causal relationship has not been established, patients should be monitored for signs and symptoms of myocardial infarction and stroke. Febuxostat is available as 40- and 80-mg tablets. The recommended starting dosage is 40 mg orally once daily. If serum uric acid concentrations are not less than 6 mg/dL after two weeks, the dosage can be increased to 80 mg orally once daily. Dosage adjustments are not needed in elderly patients or patients with mild or moderate renal or hepatic impairment. Conclusion Febuxostat is efficacious as a second-line therapy in lowering serum uric acid levels in patients with gout. Febuxostat may be an alternative for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy.
Charnelda L Gray; Nafesa E Walters-Smith
Related Documents :
7211179 - Birth order and risk of multiple sclerosis: are they associated and how?
15124759 - Influence of ccr5 delta32 polymorphism on multiple sclerosis susceptibility and disease...
11408989 - Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins.
20100229 - Relapsing neuromyelitis optica: demographic and clinical features in iranian patients.
10214759 - The evolution of neutralizing antibodies in multiple sclerosis patients treated with in...
17664149 - Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: eff...
25106709 - Cardiovascular risk factors in patients with asymptomatic primary hyperparathyroidism.
22195249 - Drug-induced liver injury: twenty five cases of acute hepatitis following ingestion of ...
23539169 - Electrodiagnostically confirmed posttraumatic neuropathy and associated clinical exam f...
Publication Detail:
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  68     ISSN:  1535-2900     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-2-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  -    
Other Details:
Languages:  ENG     Pagination:  389-398     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quantification of deficits in spatial visual function of mouse models for glaucoma.
Next Document:  Olanzapine-induced parkinsonism associated with smoking cessation.